Primary cutaneous Epstein-Barr virus-associated T-cell lymphoproliferative disorder - 2 cases with unusual, prolonged clinical course

American Journal of Dermatopathology

Volumn 32, Issue 8, 2010, Pages 832-836

  Park, Sanghui ^a   Lee, Dong Youn ^b   Kim, Won Seog ^b   Ko, Young Hyeh ^b  

^a Gachon University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Epstein Barr encoded small nuclear RNA; Epstein Barr virus; primary cutaneous T cell lymphoma

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; GENE REARRANGEMENT; HUMAN; IN SITU HYBRIDIZATION; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; T CELL LYMPHOMA; T LYMPHOCYTE;

ANTIGENS, CD3; ANTIGENS, CD56; ANTIGENS, CD8; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; RADIOTHERAPY, ADJUVANT; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650349928     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181d68381     Document Type: Article

References (27)

1. Brice SL, Jester JD, Friednash M, et al. Examination of cutaneous T-cell lymphoma for human herpes viruses by using the polymerase chain reaction. J Cutan Pathol. 1993;20:304-307.
2. Greene MH, Pinto HA, Kant JA, et al. Lymphomas and leukemias in the relatives of patients with mycosis fungoides. Cancer. 1982;49:737-741.
3. Weinstock MA. Epidemiology of mycosis fungoides. Semin Dermatol. 1994;13:154-159.
4. Agarwal S, Ramanathan U, Naresh KN. Epstein-Barr virus association and ALK gene expression in anaplastic large-cell lymphoma. Hum Pathol. 2002;33:146-152.
5. Borisch B, Boni J, Burki K, et al. Recurrent cutaneous anaplastic large cell (CD30+) lymphoma associated with Epstein-Barr virus. A case report with 9-year follow-up. Am J Surg Pathol. 1992;16:796-801.
6. Macgrogan G, Vergier B, Dubus P, et al. CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases. Am J Clin Pathol. 1996;105:440-450.
7. Iwatsuki K, Xu Z, Ohtsuka M, et al. Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview. J Dermatol Sci. 2000;22:181-195.
8. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 2000;89:2106-2116.
9. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. 1985;102:7-16.
10. Jones JF, Ray CG, Minnich LL, et al. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. 1985;102:1-7.
11. Spencer SA, Fenske NA, Espinoza CG, et al. Granuloma annulare-like eruption due to chronic Epstein-Barr virus infection. Arch Dermatol. 1988;124:250-255.
12. Labbe A, Peyrot J. Gianotti-Crosti syndrome and Epstein-Barr virus infection. J Pediatr. 1983;102:1013-1014.
13. Swerdlow SH, Harris NC, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
14. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
15. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17:1097-1107.
16. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
17. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.
18. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70-77.
19. Natkunam Y, Smoller BR, Zehnder JL, et al. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol. 1999;23:571-581.
20. Chattopadhyay A, Slater DN, Hancock BW. Cutaneous CD56 positive natural killer and cytotoxic T-cell lymphomas. Int J Oncol. 2005;26: 1559-1562.
21. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001;19:2179-2188.
22. Obama K, Tara M, Niina K. L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma. Int J Hematol. 1999;69:260-262.
23. Su IJ, Hsieh HC, Lin KH, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood. 1991;77:799-808.
24. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood. 2006;108: 4163-4169.
25. Jung CK, Lee KY, Kim Y, et al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T-and NK-cell lymphomas. Pathol Int. 2001;51:355-363.
26. Su IJ, Hsu YH, Lin MT, et al. Epstein-Barr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis. Cancer. 1993;72:2019-2027.
27. Chuang HC, Lay JD, Hsieh WC, et al. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci. 2007;98:1281-1287.